Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of “Hold” by Brokerages

Agenus Inc. (NASDAQ:AGEN) has received a consensus rating of “Hold” from the six ratings firms that are currently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $10.50.

A number of brokerages recently commented on AGEN. StockNews.com cut Agenus from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. Jefferies Financial Group reiterated a “hold” rating and issued a $7.00 price objective (up from $3.00) on shares of Agenus in a report on Friday, July 19th. HC Wainwright cut Agenus from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $40.00 to $9.00 in a report on Thursday, July 18th. Baird R W downgraded Agenus from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 19th. Finally, Robert W. Baird cut Agenus from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $35.00 to $8.00 in a research report on Friday, July 19th.

Institutional Investors Weigh In On Agenus

A number of large investors have recently added to or reduced their stakes in AGEN. Vanguard Group Inc. boosted its position in shares of Agenus by 13.7% in the first quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock valued at $19,953,000 after acquiring an additional 4,134,232 shares during the period. Key Client Fiduciary Advisors LLC increased its holdings in shares of Agenus by 38.0% during the first quarter. Key Client Fiduciary Advisors LLC now owns 858,969 shares of the biotechnology company’s stock worth $498,000 after buying an additional 236,500 shares in the last quarter. Acadian Asset Management LLC lifted its stake in shares of Agenus by 1,959.9% in the 1st quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company’s stock valued at $439,000 after acquiring an additional 720,629 shares during the last quarter. Crestline Management LP boosted its holdings in shares of Agenus by 6.5% during the 4th quarter. Crestline Management LP now owns 708,480 shares of the biotechnology company’s stock valued at $587,000 after acquiring an additional 43,480 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. grew its position in Agenus by 2.5% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 558,606 shares of the biotechnology company’s stock worth $324,000 after acquiring an additional 13,604 shares during the last quarter. Institutional investors own 61.46% of the company’s stock.

Agenus Price Performance

Agenus stock opened at $4.95 on Friday. The firm has a market capitalization of $103.95 million, a P/E ratio of -0.39 and a beta of 1.33. Agenus has a 52-week low of $4.41 and a 52-week high of $27.20. The stock has a fifty day moving average price of $8.17 and a two-hundred day moving average price of $10.86.

Agenus (NASDAQ:AGEN) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($2.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.33) by ($1.19). The firm had revenue of $23.51 million for the quarter, compared to the consensus estimate of $64.73 million. During the same quarter last year, the firm earned ($4.00) EPS. On average, equities research analysts predict that Agenus will post -10.87 EPS for the current fiscal year.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.